Global Oncolytic Virus Cancer Immunotherapy Market Research Report 2023

Report ID: 2006094 | Published Date: Sep 2024 | No. of Page: 87 | Base Year: 2023 | Rating: 4.3 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
        1.2.2 Monoclonal Antibodies
        1.2.3 Checkpoint Inhibitors
        1.2.4 Oncoloytic Viral Therapies and Cancer Vaccines
    1.3 Market by Application
        1.3.1 Global Oncolytic Virus Cancer Immunotherapy Market Growth by Application: 2018 VS 2022 VS 2029
        1.3.2 Lung Cancer
        1.3.3 Breast Cancer
        1.3.4 Colorectal Cancer
        1.3.5 Melanoma
        1.3.6 Prostate Cancer
        1.3.7 Head and neck Cancer
        1.3.8 Ovarian Cancer
        1.3.9 Pancreatic Cancer
        1.3.10 Others
    1.4 Study Objectives
    1.5 Years Considered
    1.6 Years Considered
2 Global Growth Trends
    2.1 Global Oncolytic Virus Cancer Immunotherapy Market Perspective (2018-2029)
    2.2 Oncolytic Virus Cancer Immunotherapy Growth Trends by Region
        2.2.1 Global Oncolytic Virus Cancer Immunotherapy Market Size by Region: 2018 VS 2022 VS 2029
        2.2.2 Oncolytic Virus Cancer Immunotherapy Historic Market Size by Region (2018-2023)
        2.2.3 Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Region (2024-2029)
    2.3 Oncolytic Virus Cancer Immunotherapy Market Dynamics
        2.3.1 Oncolytic Virus Cancer Immunotherapy Industry Trends
        2.3.2 Oncolytic Virus Cancer Immunotherapy Market Drivers
        2.3.3 Oncolytic Virus Cancer Immunotherapy Market Challenges
        2.3.4 Oncolytic Virus Cancer Immunotherapy Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Oncolytic Virus Cancer Immunotherapy Players by Revenue
        3.1.1 Global Top Oncolytic Virus Cancer Immunotherapy Players by Revenue (2018-2023)
        3.1.2 Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Players (2018-2023)
    3.2 Global Oncolytic Virus Cancer Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Oncolytic Virus Cancer Immunotherapy Revenue
    3.4 Global Oncolytic Virus Cancer Immunotherapy Market Concentration Ratio
        3.4.1 Global Oncolytic Virus Cancer Immunotherapy Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Oncolytic Virus Cancer Immunotherapy Revenue in 2022
    3.5 Oncolytic Virus Cancer Immunotherapy Key Players Head office and Area Served
    3.6 Key Players Oncolytic Virus Cancer Immunotherapy Product Solution and Service
    3.7 Date of Enter into Oncolytic Virus Cancer Immunotherapy Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Oncolytic Virus Cancer Immunotherapy Breakdown Data by Type
    4.1 Global Oncolytic Virus Cancer Immunotherapy Historic Market Size by Type (2018-2023)
    4.2 Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Type (2024-2029)
5 Oncolytic Virus Cancer Immunotherapy Breakdown Data by Application
    5.1 Global Oncolytic Virus Cancer Immunotherapy Historic Market Size by Application (2018-2023)
    5.2 Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Application (2024-2029)
6 North America
    6.1 North America Oncolytic Virus Cancer Immunotherapy Market Size (2018-2029)
    6.2 North America Oncolytic Virus Cancer Immunotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
    6.3 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023)
    6.4 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2024-2029)
    6.5 United States
    6.6 Canada
7 Europe
    7.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size (2018-2029)
    7.2 Europe Oncolytic Virus Cancer Immunotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
    7.3 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023)
    7.4 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2024-2029)
    7.5 Germany
    7.6 France
    7.7 U.K.
    7.8 Italy
    7.9 Russia
    7.10 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size (2018-2029)
    8.2 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Growth Rate by Region: 2018 VS 2022 VS 2029
    8.3 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2018-2023)
    8.4 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2024-2029)
    8.5 China
    8.6 Japan
    8.7 South Korea
    8.8 Southeast Asia
    8.9 India
    8.10 Australia
9 Latin America
    9.1 Latin America Oncolytic Virus Cancer Immunotherapy Market Size (2018-2029)
    9.2 Latin America Oncolytic Virus Cancer Immunotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
    9.3 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023)
    9.4 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2024-2029)
    9.5 Mexico
    9.6 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size (2018-2029)
    10.2 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
    10.3 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023)
    10.4 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2024-2029)
    10.5 Turkey
    10.6 Saudi Arabia
    10.7 UAE
11 Key Players Profiles
    11.1 AstraZeneca
        11.1.1 AstraZeneca Company Detail
        11.1.2 AstraZeneca Business Overview
        11.1.3 AstraZeneca Oncolytic Virus Cancer Immunotherapy Introduction
        11.1.4 AstraZeneca Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
        11.1.5 AstraZeneca Recent Development
    11.2 Amgen
        11.2.1 Amgen Company Detail
        11.2.2 Amgen Business Overview
        11.2.3 Amgen Oncolytic Virus Cancer Immunotherapy Introduction
        11.2.4 Amgen Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
        11.2.5 Amgen Recent Development
    11.3 F Hoffman-La Roche
        11.3.1 F Hoffman-La Roche Company Detail
        11.3.2 F Hoffman-La Roche Business Overview
        11.3.3 F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Introduction
        11.3.4 F Hoffman-La Roche Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
        11.3.5 F Hoffman-La Roche Recent Development
    11.4 Bristol-Myers Squibb
        11.4.1 Bristol-Myers Squibb Company Detail
        11.4.2 Bristol-Myers Squibb Business Overview
        11.4.3 Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Introduction
        11.4.4 Bristol-Myers Squibb Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
        11.4.5 Bristol-Myers Squibb Recent Development
    11.5 Novartis AG
        11.5.1 Novartis AG Company Detail
        11.5.2 Novartis AG Business Overview
        11.5.3 Novartis AG Oncolytic Virus Cancer Immunotherapy Introduction
        11.5.4 Novartis AG Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
        11.5.5 Novartis AG Recent Development
    11.6 Merck & Co., Inc.
        11.6.1 Merck & Co., Inc. Company Detail
        11.6.2 Merck & Co., Inc. Business Overview
        11.6.3 Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Introduction
        11.6.4 Merck & Co., Inc. Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
        11.6.5 Merck & Co., Inc. Recent Development
    11.7 Pfizer
        11.7.1 Pfizer Company Detail
        11.7.2 Pfizer Business Overview
        11.7.3 Pfizer Oncolytic Virus Cancer Immunotherapy Introduction
        11.7.4 Pfizer Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
        11.7.5 Pfizer Recent Development
    11.8 Biovex
        11.8.1 Biovex Company Detail
        11.8.2 Biovex Business Overview
        11.8.3 Biovex Oncolytic Virus Cancer Immunotherapy Introduction
        11.8.4 Biovex Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
        11.8.5 Biovex Recent Development
    11.9 Cell Genesys
        11.9.1 Cell Genesys Company Detail
        11.9.2 Cell Genesys Business Overview
        11.9.3 Cell Genesys Oncolytic Virus Cancer Immunotherapy Introduction
        11.9.4 Cell Genesys Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
        11.9.5 Cell Genesys Recent Development
    11.10 Crusade Laboratories
        11.10.1 Crusade Laboratories Company Detail
        11.10.2 Crusade Laboratories Business Overview
        11.10.3 Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Introduction
        11.10.4 Crusade Laboratories Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
        11.10.5 Crusade Laboratories Recent Development
    11.11 Genelux Corporation
        11.11.1 Genelux Corporation Company Detail
        11.11.2 Genelux Corporation Business Overview
        11.11.3 Genelux Corporation Oncolytic Virus Cancer Immunotherapy Introduction
        11.11.4 Genelux Corporation Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
        11.11.5 Genelux Corporation Recent Development
    11.12 Lokon Pharma
        11.12.1 Lokon Pharma Company Detail
        11.12.2 Lokon Pharma Business Overview
        11.12.3 Lokon Pharma Oncolytic Virus Cancer Immunotherapy Introduction
        11.12.4 Lokon Pharma Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
        11.12.5 Lokon Pharma Recent Development
    11.13 MultiVir
        11.13.1 MultiVir Company Detail
        11.13.2 MultiVir Business Overview
        11.13.3 MultiVir Oncolytic Virus Cancer Immunotherapy Introduction
        11.13.4 MultiVir Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
        11.13.5 MultiVir Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

List of Tables
    Table 1. Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
    Table 2. Key Players of Monoclonal Antibodies
    Table 3. Key Players of Checkpoint Inhibitors
    Table 4. Key Players of Oncoloytic Viral Therapies and Cancer Vaccines
    Table 5. Global Oncolytic Virus Cancer Immunotherapy Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
    Table 6. Global Oncolytic Virus Cancer Immunotherapy Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 7. Global Oncolytic Virus Cancer Immunotherapy Market Size by Region (2018-2023) & (US$ Million)
    Table 8. Global Oncolytic Virus Cancer Immunotherapy Market Share by Region (2018-2023)
    Table 9. Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Region (2024-2029) & (US$ Million)
    Table 10. Global Oncolytic Virus Cancer Immunotherapy Market Share by Region (2024-2029)
    Table 11. Oncolytic Virus Cancer Immunotherapy Market Trends
    Table 12. Oncolytic Virus Cancer Immunotherapy Market Drivers
    Table 13. Oncolytic Virus Cancer Immunotherapy Market Challenges
    Table 14. Oncolytic Virus Cancer Immunotherapy Market Restraints
    Table 15. Global Oncolytic Virus Cancer Immunotherapy Revenue by Players (2018-2023) & (US$ Million)
    Table 16. Global Oncolytic Virus Cancer Immunotherapy Market Share by Players (2018-2023)
    Table 17. Global Top Oncolytic Virus Cancer Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus Cancer Immunotherapy as of 2022)
    Table 18. Ranking of Global Top Oncolytic Virus Cancer Immunotherapy Companies by Revenue (US$ Million) in 2022
    Table 19. Global 5 Largest Players Market Share by Oncolytic Virus Cancer Immunotherapy Revenue (CR5 and HHI) & (2018-2023)
    Table 20. Key Players Headquarters and Area Served
    Table 21. Key Players Oncolytic Virus Cancer Immunotherapy Product Solution and Service
    Table 22. Date of Enter into Oncolytic Virus Cancer Immunotherapy Market
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Oncolytic Virus Cancer Immunotherapy Market Size by Type (2018-2023) & (US$ Million)
    Table 25. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Type (2018-2023)
    Table 26. Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Type (2024-2029) & (US$ Million)
    Table 27. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Type (2024-2029)
    Table 28. Global Oncolytic Virus Cancer Immunotherapy Market Size by Application (2018-2023) & (US$ Million)
    Table 29. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Application (2018-2023)
    Table 30. Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Application (2024-2029) & (US$ Million)
    Table 31. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Application (2024-2029)
    Table 32. North America Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 33. North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023) & (US$ Million)
    Table 34. North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2024-2029) & (US$ Million)
    Table 35. Europe Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 36. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023) & (US$ Million)
    Table 37. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2024-2029) & (US$ Million)
    Table 38. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 39. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2018-2023) & (US$ Million)
    Table 40. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2024-2029) & (US$ Million)
    Table 41. Latin America Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 42. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023) & (US$ Million)
    Table 43. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2024-2029) & (US$ Million)
    Table 44. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 45. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023) & (US$ Million)
    Table 46. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2024-2029) & (US$ Million)
    Table 47. AstraZeneca Company Detail
    Table 48. AstraZeneca Business Overview
    Table 49. AstraZeneca Oncolytic Virus Cancer Immunotherapy Product
    Table 50. AstraZeneca Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
    Table 51. AstraZeneca Recent Development
    Table 52. Amgen Company Detail
    Table 53. Amgen Business Overview
    Table 54. Amgen Oncolytic Virus Cancer Immunotherapy Product
    Table 55. Amgen Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
    Table 56. Amgen Recent Development
    Table 57. F Hoffman-La Roche Company Detail
    Table 58. F Hoffman-La Roche Business Overview
    Table 59. F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Product
    Table 60. F Hoffman-La Roche Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
    Table 61. F Hoffman-La Roche Recent Development
    Table 62. Bristol-Myers Squibb Company Detail
    Table 63. Bristol-Myers Squibb Business Overview
    Table 64. Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Product
    Table 65. Bristol-Myers Squibb Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
    Table 66. Bristol-Myers Squibb Recent Development
    Table 67. Novartis AG Company Detail
    Table 68. Novartis AG Business Overview
    Table 69. Novartis AG Oncolytic Virus Cancer Immunotherapy Product
    Table 70. Novartis AG Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
    Table 71. Novartis AG Recent Development
    Table 72. Merck & Co., Inc. Company Detail
    Table 73. Merck & Co., Inc. Business Overview
    Table 74. Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Product
    Table 75. Merck & Co., Inc. Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
    Table 76. Merck & Co., Inc. Recent Development
    Table 77. Pfizer Company Detail
    Table 78. Pfizer Business Overview
    Table 79. Pfizer Oncolytic Virus Cancer Immunotherapy Product
    Table 80. Pfizer Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
    Table 81. Pfizer Recent Development
    Table 82. Biovex Company Detail
    Table 83. Biovex Business Overview
    Table 84. Biovex Oncolytic Virus Cancer Immunotherapy Product
    Table 85. Biovex Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
    Table 86. Biovex Recent Development
    Table 87. Cell Genesys Company Detail
    Table 88. Cell Genesys Business Overview
    Table 89. Cell Genesys Oncolytic Virus Cancer Immunotherapy Product
    Table 90. Cell Genesys Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
    Table 91. Cell Genesys Recent Development
    Table 92. Crusade Laboratories Company Detail
    Table 93. Crusade Laboratories Business Overview
    Table 94. Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Product
    Table 95. Crusade Laboratories Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
    Table 96. Crusade Laboratories Recent Development
    Table 97. Genelux Corporation Company Detail
    Table 98. Genelux Corporation Business Overview
    Table 99. Genelux Corporation Oncolytic Virus Cancer Immunotherapy Product
    Table 100. Genelux Corporation Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
    Table 101. Genelux Corporation Recent Development
    Table 102. Lokon Pharma Company Detail
    Table 103. Lokon Pharma Business Overview
    Table 104. Lokon Pharma Oncolytic Virus Cancer Immunotherapy Product
    Table 105. Lokon Pharma Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
    Table 106. Lokon Pharma Recent Development
    Table 107. MultiVir Company Detail
    Table 108. MultiVir Business Overview
    Table 109. MultiVir Oncolytic Virus Cancer Immunotherapy Product
    Table 110. MultiVir Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
    Table 111. MultiVir Recent Development
    Table 112. Research Programs/Design for This Report
    Table 113. Key Data Information from Secondary Sources
    Table 114. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Oncolytic Virus Cancer Immunotherapy Market Size Comparison by Type (2023-2029) & (US$ Million)
    Figure 2. Global Oncolytic Virus Cancer Immunotherapy Market Share by Type: 2022 VS 2029
    Figure 3. Monoclonal Antibodies Features
    Figure 4. Checkpoint Inhibitors Features
    Figure 5. Oncoloytic Viral Therapies and Cancer Vaccines Features
    Figure 6. Global Oncolytic Virus Cancer Immunotherapy Market Size Comparison by Application (2023-2029) & (US$ Million)
    Figure 7. Global Oncolytic Virus Cancer Immunotherapy Market Share by Application: 2022 VS 2029
    Figure 8. Lung Cancer Case Studies
    Figure 9. Breast Cancer Case Studies
    Figure 10. Colorectal Cancer Case Studies
    Figure 11. Melanoma Case Studies
    Figure 12. Prostate Cancer Case Studies
    Figure 13. Head and neck Cancer Case Studies
    Figure 14. Ovarian Cancer Case Studies
    Figure 15. Pancreatic Cancer Case Studies
    Figure 16. Others Case Studies
    Figure 17. Oncolytic Virus Cancer Immunotherapy Report Years Considered
    Figure 18. Global Oncolytic Virus Cancer Immunotherapy Market Size (US$ Million), Year-over-Year: 2018-2029
    Figure 19. Global Oncolytic Virus Cancer Immunotherapy Market Size, (US$ Million), 2018 VS 2022 VS 2029
    Figure 20. Global Oncolytic Virus Cancer Immunotherapy Market Share by Region: 2022 VS 2029
    Figure 21. Global Oncolytic Virus Cancer Immunotherapy Market Share by Players in 2022
    Figure 22. Global Top Oncolytic Virus Cancer Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus Cancer Immunotherapy as of 2022)
    Figure 23. The Top 10 and 5 Players Market Share by Oncolytic Virus Cancer Immunotherapy Revenue in 2022
    Figure 24. North America Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 25. North America Oncolytic Virus Cancer Immunotherapy Market Share by Country (2018-2029)
    Figure 26. United States Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 27. Canada Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 28. Europe Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 29. Europe Oncolytic Virus Cancer Immunotherapy Market Share by Country (2018-2029)
    Figure 30. Germany Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 31. France Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 32. U.K. Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 33. Italy Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 34. Russia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 35. Nordic Countries Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 36. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 37. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Share by Region (2018-2029)
    Figure 38. China Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 39. Japan Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 40. South Korea Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 41. Southeast Asia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 42. India Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 43. Australia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 44. Latin America Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 45. Latin America Oncolytic Virus Cancer Immunotherapy Market Share by Country (2018-2029)
    Figure 46. Mexico Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 47. Brazil Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 48. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 49. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Share by Country (2018-2029)
    Figure 50. Turkey Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 51. Saudi Arabia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 52. AstraZeneca Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
    Figure 53. Amgen Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
    Figure 54. F Hoffman-La Roche Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
    Figure 55. Bristol-Myers Squibb Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
    Figure 56. Novartis AG Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
    Figure 57. Merck & Co., Inc. Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
    Figure 58. Pfizer Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
    Figure 59. Biovex Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
    Figure 60. Cell Genesys Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
    Figure 61. Crusade Laboratories Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
    Figure 62. Genelux Corporation Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
    Figure 63. Lokon Pharma Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
    Figure 64. MultiVir Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
    Figure 65. Bottom-up and Top-down Approaches for This Report
    Figure 66. Data Triangulation
    Figure 67. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
AstraZeneca
Amgen
F Hoffman-La Roche
Bristol-Myers Squibb
Novartis AG
Merck & Co., Inc.
Pfizer
Biovex
Cell Genesys
Crusade Laboratories
Genelux Corporation
Lokon Pharma
MultiVir
Frequently Asked Questions
Oncolytic Virus Cancer Immunotherapy report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Oncolytic Virus Cancer Immunotherapy report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Oncolytic Virus Cancer Immunotherapy report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports